Study procedures
toxicity, fatigue, alopecia, nausea,
ADVERSE EVENT, ALOPECIA, BRAIN
The recommended dose for phase II trial was determined to be 4 mg/kg weekly according to the first in human trial.Follow‐up included a weekly physical, neurologic examination, complete blood counts, and a chemical battery every 2 weeks. Brain imaging (MRI) was performed every 8 weeks. Treatment response was evaluated according to RANO criteria.Treatment was interrupted for Common Terminology Criteria for Adverse Events (AEs) version 4.03 Grade 3 drug‐related non‐hematologic toxicity (except alopecia, nausea, vomiting, and fatigue). Treatment was resumed at the physician's discretion and a dose reduction was permitted up to 2 mg/kg (1 mg/kg at each decision). Patients who experienced three or more sequential interruptions in treatment were permanently excluded from the study.